截至8月27日收盘，基因测序概念下跌3.38%，位居概念板块跌幅榜前列，板块内，广生堂、睿昂基 因、谱尼测试等跌幅居前，股价上涨的有6只，涨幅居前的有迪安诊断、埃科光电、金域医学等，分别 上涨5.81%、3.67%、2.11%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | F5G概念 | 0.46 | 钛白粉概念 | -3.88 | | 中国AI 50 | 0.36 | 兵装重组概念 | -3.63 | | 共封装光学(CPO) | 0.18 | 天津自贸区 | -3.49 | | 稀土永磁 | 0.10 | 太赫兹 | -3.40 | | 智能音箱 | -0.27 | 基因测序 | -3.38 | | WiFi 6 | -0.46 | 细胞免疫治疗 | -3.29 | | MLOps概念 | -0.49 | 猴痘概念 | -3.25 | | 星闪概念 | -0.62 | 血氧仪 | -3.25 | | MCU芯片 | -0.66 | 幽门螺杆菌概念 | -3.24 | | 国家大基金持股 | -0.72 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

截至6月30日，九州通股东户数4.17万，较上期减少12.92%；人均流通股120824股，较上期增加 14.84%。2025年1月-6月，九州通实现营业收入811.06亿元，同比增长5.10%；归母净利润14.46亿元，同 比增长19.70%。 8月26日，九州通涨0.00%，成交额3.19亿元。两融数据显示，当日九州通获融资买入额3898.18万元， 融资偿还1995.17万元，融资净买入1903.00万元。截至8月26日，九州通融资融券余额合计6.42亿元。 融资方面，九州通当日融资买入3898.18万元。当前融资余额6.37亿元，占流通市值的2.32%，融资余额 低于近一年20%分位水平，处于低位。 融券方面，九州通8月26日融券偿还3300.00股，融券卖出19.17万股，按当日收盘价计算，卖出金额 104.28万元；融券余量91.26万股，融券余额496.47万元，超过近一年90%分位水平，处于高位。 资料显示，九州通医药集团股份有限公司位于湖北省武汉市汉阳区龙兴西街5号，成立日期1999年3月9 日，上市日期2010年11月2日，公司主营业务涉及数字化医药分销与供应链业务、总代品牌推广业务、 医 ...

公司股东户数为4.17万户，前十大股东持股数量为32.06亿股，占总股本比例为63.59%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 上海弘康实业投资有限公司 | 21.5 | | 2 | 狮龙国际集团(香港)有限公司 | 11.4 | | 3 | 楚昌投资集团有限公司 | 7.19 | | ব | 中山广银投资有限公司 | 6.65 | | 5 | 北京点金投资有限公司 | 5.48 | | 6 | 中国信达资产管理股份有限公司 | 5.00 | | 7 | 香港中央结算有限公司 | 1.79 | | 8 | 九州通医药集团股份有限公司-2023-2025年员工持股计划 | 1.72 | | g | 刘树林 | 1.40 | | 10 | 长城国泰(舟山)产业并购重组基金合伙企业(有限合伙) | 1.36 | 公司最新资产负债率为67.97%，较上季度资产负债率减少0.09个百分点，较去年同期资产负债率减少1.03个百分点。 公司最新毛利率为7.56%，较上季度毛利率增加0.23个百分点。最新ROE为5.21%，较去年同期ROE增加0 ...

Growth - Shudao Equipment reported a net profit of 10.15 million yuan in the first half of the year, a year-on-year increase of 5972.30% [1] - Aerospace Science and Technology achieved a net profit of 88.97 million yuan, up 2161.91% year-on-year [1] - Tianbao Infrastructure's net profit reached 118 million yuan, growing by 2106.58% year-on-year [1] - Northern Rare Earth reported a net profit of 931 million yuan, an increase of 1951.52% year-on-year [1] - Liugang Co., Ltd. posted a net profit of 36.8 million yuan, up 579.54% year-on-year [1] - Cheng Tian Wei Ye's net profit was 10.88 million yuan, increasing by 562.05% year-on-year [1] - Perfect World reported a net profit of 503 million yuan, a year-on-year increase of 384.52% [1] - Shenghong Technology achieved a net profit of 2.143 billion yuan, up 366.89% year-on-year [1] - Zhongke Magnetic Industry's net profit was 20.90 million yuan, increasing by 271.78% year-on-year [1] - Xinjiang Communications Construction reported a net profit of 255 million yuan, up 255.25% year-on-year [1] - Shennong Group achieved a net profit of 388 million yuan, a year-on-year increase of 212.65% [1] - Daikin Heavy Industries reported a net profit of 547 million yuan, up 214.32% year-on-year [1] - Fostar's net profit was 251 million yuan, increasing by 140.45% year-on-year [1] - Guohua Airlines achieved a net profit of 1.24 billion yuan, up 86.15% year-on-year [1] - China Electric Port reported a net profit of 181 million yuan, increasing by 64.98% year-on-year [1] - Ailisi's net profit was 1.051 billion yuan, up 60.22% year-on-year [1] - Zijin Mining reported a net profit of 23.292 billion yuan, a year-on-year increase of 54.41% [1] - Zhongke Chuangda achieved a net profit of 158 million yuan, up 51.84% year-on-year [1] - Sichuan Gold reported a net profit of 209 million yuan, increasing by 48.41% year-on-year [1] - Dongxing Securities achieved a net profit of 819 million yuan, up 42.12% year-on-year [1] - Fosun Pharma reported a net profit of 1.702 billion yuan, a year-on-year increase of 38.96% [1] - Kotec Power's net profit was 23.99 million yuan, increasing by 35.52% year-on-year [1] - Dongshan Precision reported a net profit of 758 million yuan, up 35.21% year-on-year [1] - Inspur Information achieved a net profit of 799 million yuan, a year-on-year increase of 34.87% [1] - Shenzhen Huaqiang reported a net profit of 236 million yuan, increasing by 33.45% year-on-year [1] - Conch Cement achieved a net profit of 4.368 billion yuan, up 31.34% year-on-year [1] - Jiuzhoutong reported a net profit of 1.446 billion yuan, increasing by 19.7% year-on-year [1] - Aofei Data achieved a net profit of 87.89 million yuan, a year-on-year increase of 16.09% [2] Decline and Loss - Huachang Chemical reported a net profit of 1.09 million yuan, a year-on-year decrease of 97.58% [2] - Meibang Apparel achieved a net profit of 993,030 yuan, down 87.07% year-on-year [2] - Toukeng Life reported a net profit of 275,930 yuan, a decrease of 58.41% year-on-year [2] - BlueFocus reported a net profit of 96.44 million yuan, down 47.33% year-on-year [2] - China Gold achieved a net profit of 31.9 million yuan, a decrease of 46.35% year-on-year [2] - Huaxi Biological reported a net profit of 22.1 million yuan, down 35.38% year-on-year [2] - Zhejiang New Energy achieved a net profit of 29.2 million yuan, down 34.65% year-on-year [2] - Hainan Mining reported a net profit of 28.1 million yuan, a decrease of 30.36% year-on-year [2] - Changying Precision achieved a net profit of 30.6 million yuan, down 29.37% year-on-year [2] - China Duty Free reported a net profit of 2.6 billion yuan, down 20.81% year-on-year [2] - Jiangling Motors achieved a net profit of 73.3 million yuan, down 18.17% year-on-year [2] - Donghua Software reported a net profit of 24.4 million yuan, down 15.78% year-on-year [2] - Hengda New Materials achieved a net profit of 3.4235 million yuan, down 12.68% year-on-year [2] - Yaoji Technology reported a net profit of 25.6 million yuan, down 9.98% year-on-year [2] - Ping An Insurance achieved a net profit of 68.047 billion yuan, down 8.8% year-on-year [2] - China Petroleum reported a net profit of 840.07 billion yuan, down 5.4% year-on-year [2] - 360 reported a net loss of 28.2 million yuan [2] - Electric Wind Power reported a net loss of 27.9 million yuan [2] Losses - Suzhou Keda reported a net loss of 21.7 million yuan [3] - Yuntian Lifa achieved a net loss of 20.6 million yuan [3] - Kosen Technology reported a net loss of 10.5 million yuan [3] - Xinyada reported a net loss of 5.2635 million yuan [3] - Chengfei Integration achieved a net loss of 1.49208 million yuan [3] - China Film reported a net loss of 11 million yuan, turning from profit to loss year-on-year [3]

格隆汇8月26日丨九州通(600998.SH)发布中报，2025上半年实现营业总收入811.06亿元，同比增长 5.1%；归属母公司股东净利润14.46亿元，同比增长19.7%；基本每股收益为0.29元。 ...

其中，在新产品战略方面，九州通发挥全集团相关业务组织整合资源优势，已形成以CSO为核心的新产 品业务组织矩阵，采用独家代理、股权合作、买断权利、自主研发等多种形式，获取兼具临床价值和市 场空间，并且适合于公司的新产品。报告期内，公司新增引进药品新品61个，总代品牌推广业务（含药 品及医疗器械）销售收入达95.91亿元。 新零售战略方面，九州通以好药师"万店加盟"为核心，形成包含B2C电商总代总销、药九九B2B电商平 台、零售电商等业务矩阵，打造触及C端客户的全方位、全场景的"线上线下（300959）一体化"新零售 服务体系。上半年，面向C端的新零售业务实现销售收入14.93亿元（含B2C电商总代总销等业务），同 比增长2.52%。 截至2025年6月底，好药师直营及加盟药店门店总数达31,535家，预计2025年末门店数将超33,500家。与 此同时，好药师开始注重经营质量的提升，积极拓展合作供应商，全国累计拥有超800家品牌供应商为 加盟店提供强力品牌品种保障，已引进定制品种76个，集采战略合作KA政策品种累计达625个。上半年 公司向加盟药店销售收入达34.18亿元，同比增长41.30%。 8月26日晚间 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-061 九州通医药集团股份有限公司 第六届董事会第十六次会议决议公告 经过审议并表决，本次会议通过了以下议案： 一、《关于公司 2025 年半年度报告及摘要的议案》 董事会审议通过了《九州通 2025 年半年度报告》及摘要，公司上半年经营 业绩分析如下： 2025 年上半年，公司实现营业收入和归母净利润的双增长，营业收入 811.06 亿元，同比增长 5.10%；归母净利润 14.46 亿元，同比增长 19.70%；公司经营活 动产生的现金流量净额较上年同期增加 3.8 亿元，预计全年经营活动产生的现金 流量净额为与经营业绩相匹配的正数。 2025 年上半年，公司各业务板块齐头并进，实现良好发展。医药分销核心 业务实现销售收入 676.34 亿元，同比增长 6.04%，，为公司整体营业收入增长奠 定较好基础；此外，医药工业、数字物流等新兴业务板块均实现较快增长，其中 医药工业自产及 OEM 业务形成具有市场竞争力的西药、中药及器械产品集群， 半年度实现销售收入 15.93 亿元，同比增长 10.77%；医药新零售业务上半年实现 销售收入 14. ...

九州通医药集团股份有限公司 2025 年半年度报告 九州通医药集团股份有限公司 2025 年半年度报告 公司代码：600998 公司简称：九州通 九州通医药集团股份有限公司 九州通医药集团股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人刘长云、主管会计工作负责人夏晓益及会计机构负责人（会计主管人员）夏晓益 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期内，公司未有经董事会审议的半年度利润分配预案或公积金转增股本预案。 六、 前瞻性陈述的风险声明 √适用 □不适用 本半年度报告中涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺 ，请投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上 ...

稀释每股收益（元／股 公司主要会计数据和财务指标的说明 下简称"归母净利润"）较上年同期增长 19.70%，主要原因是公司在保持医药分销收入稳健增长 的同时，医药工业、数字物流等新兴业务板块收入分别实现 10.77%、24.66%的较快增长；同时， 公司完成医药仓储物流基础设施公募 REITs 发行上市，增加公司净利润 4.38 亿元。 九州通医药集团股份有限公司 2025 年半年度报告摘要 润"）较上年同期下降 19.34%，主要原因是防疫物资应收账款及医院客户账期延长等所致减值准 备计提增加，对公司扣非归母净利润造成了一定影响。如剔除前述减值准备计提增加因素的影响， 公司本报告期归母净利润 15.87 亿元，同比增长 31.44%；扣非归母净利润 10.94 亿元，同比下降 本年中较上年同期加大了应收账款的清收力度，现金回款增加所致。预计全年经营活动产生的现 金流量净额为与经营业绩相匹配的正数。 两化"）战略以及"三花"（花时间、花精力、花成本）人才战略方面的投入，也对公司扣非归 母净利润造成了一定影响。上半年，公司在药九九 B2B、好药师零售、京丰制药等"三新两化" 战略实施主体的人工成本投入达 2.4 ...